Terms: = Head and neck cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Clinical Outcome
4 results:
1. CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
Melchardt T; Hufnagl C; Magnes T; Weiss L; Hutarew G; Neureiter D; Schlattau A; Moser G; Gaggl A; Tränkenschuh W; Greil R; Egle A
BMC Cancer; 2015 Oct; 15():725. PubMed ID: 26475344
[TBL] [Abstract] [Full Text] [Related]
2. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract] [Full Text] [Related]
3. Polymorphisms in GSTM1 and xpd genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy.
Mahimkar MB; Samant TA; Kannan S; Tulsulkar J; Pai PS; Anantharaman D
Mol Carcinog; 2012 Oct; 51 Suppl 1():E94-103. PubMed ID: 22213390
[TBL] [Abstract] [Full Text] [Related]
4. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract] [Full Text] [Related]
